Amrutanjan Health Care Limited — PPTs, 13-11-2024: Investor Presentation

**Financial Highlights:** In Q2 FY25, Amrutanjan Health Care Limited reported a net sales increase of 10.68% to ₹109.92 Cr, with profit before tax rising 73.07% to ₹15.94 Cr, and profit after tax up 72.26% to ₹11.80 Cr. For H1 FY25, net sales grew 9.30% to ₹193.65 Cr, leading to a profit before tax of ₹22.29 Cr, a 19.58% increase year-over-year.

**Strategic Initiatives and Growth Drivers:** The company's focus on expanding distribution, particularly in non-metro areas, has strengthened its market position, driving substantial growth across categories. The OTC segment, especially the Back Pain Roll-On, showcased strong sales due to increased visibility and consumer demand.

**Business Developments:** AHCL introduced a new 2.5ml SKU for the AFRR variant aimed at the low-town class, demonstrating a strategic shift to capture emerging consumer preferences. The Comfy brand maintained significant growth momentum, achieving a 30% increase in H1 FY25.

**Market Position and Competitive Advantage:** AHCL continues to lead the roll-on segment with a 69% market share, benefitting from effective distribution strategies. The company's responses to emerging trends, such as bulk-pack preferences in women's hygiene, have further solidified its competitive edge.

**Investor Implications:** The positive financial performance indicates robust growth prospects for AHCL, bolstered by a strategic focus on operational efficiency and expanding market reach. Investors may find potential in the company's commitment to innovation and market responsiveness.